Short answer
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed an 8-K current report with the SEC on October 5, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Updated investor presentation for healthcare conferences, analysts, and stockholders.
IOVANCE BIOTHERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Updated investor presentation for healthcare conferences, analysts, and stockholders
- Exhibit 99.1 contains the substantive presentation and may include updated clinical or corporate information
- October 5, 2026 update, potentially relevant to Iovance’s messaging and investor expectations
Item EX-99.1 · Exhibit EX-99.1
- Full-year 2026 revenue guidance raised to $410M-$420M, midpoint up $55M, or approximately 15%, from $350M-$370M
- 2Q26 revenue approximately $304M, more than 10% above guidance, supporting Amtagvi commercial momentum
- Approximately $304M cash and runway into 2H28, reducing near-term financing pressure
- Approximately 100 authorized treatment centers as of October 5, 2026, expanding patient access and commercial capacity
- Pipeline broadening beyond melanoma, with potential NSCLC launch in 2H27 and registrational sarcoma program started in 2Q26
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other IOVANCE BIOTHERAPEUTICS, INC. 8-K filings
Get the next IOVA 8-K as it lands
Follow IOVA for push alerts, or ask the research agent what this filing means.